Abstract | PURPOSE: METHODS: BALB/c mice were divided into 5 groups: contol (CON), Dermatophagoides farinae (Derf), AR mice treated with AEBSF before sensitization (S), AR mice treated with AEBSF after challenge (C), and steroid groups. Derf was used as an allergen. AEBSF was administered before S or after C. Allergic symptom scores, eosinophil counts, proteolytic activity, interferon-γ, interleukin (IL)-10 levels and serum Derf-specific IgE levels were measured. T-bet, GATA-3, Foxp3, IL-13, and transforming growth factor (TGF)-β mRNA levels were determined using real-time polymerase chain reaction. CD4(+)CD25(+)Foxp3(+) T cells were assessed using flow cytometry. RESULTS: Symptom scores, serum Derf-specific IgE levels, GATA-3 mRNA levels, IL-13 mRNA levels, and tissue eosinophil counts decreased in both the S and C groups (P<0.05). Additionally, the percentage of CD4(+)CD25(+)Foxp3(+) T cells, IL-10 levels, and Foxp3 mRNA levels increased in the S and C groups compared with those in the Derf group (P<0.05). AEBSF treatment decreased the proteolytic activity in the S and C groups (P<0.05). CONCLUSIONS: Prophylactic and therapeutic treatment with AEBSF significantly reduces allergic airway inflammation and can induce regulatory T cells in a murine model of AR.
|
Authors | Boo-Young Kim, Hyang Rim Park, Ji-Hyeon Shin, Sung Won Kim, Jin Hee Cho, Yong Jin Park, Soo Whan Kim |
Journal | Allergy, asthma & immunology research
(Allergy Asthma Immunol Res)
Vol. 6
Issue 6
Pg. 558-66
(Nov 2014)
ISSN: 2092-7355 [Print] Korea (South) |
PMID | 25374756
(Publication Type: Journal Article)
|